Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.65) by 4.62 percent. This is a 5.56 percent increase over losses of $(0.72) per share from the same period last year. The company reported quarterly sales of $3.604 million which missed the analyst consensus estimate of $14.613 million by 75.34 percent.